In-silico trials refers to the development of patient-specific cohorts for testing the safety and/or efficacy of new drugs and medical devices. Also, with the development of computational modelling and simulation entire imaging including source, object, detection, and image interpretation components intended for R&D, optimization, technology assessment, and regulatory evaluation can be achieved.
Certera Inc. and Dassault Systèmes- Notable Market Players in In-Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market
The in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is majorly comprised of top players involving InSilico Trials Technologies, Feops, CADFEM Medical GmbH, Dassault Systèmes, Virtonomy GmbH, Certara Inc., Computational Life, NOVA, TwInsight Medical, Ansys, Inc.; Synopsys, Inc; Sensyne Health plc, Phesi, Tempus, and Cerner Corporation, amongst others.
The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the fall management market:
| Year | News |
| October-2021 | InSilico Trial Technologies, announced launching of two new simulation tools intended for oncology that have no equals on the market namely, “PCa GnRH Agonists Simulator” and “CTx NeutroSim”. These tools accelerate the growth of this startup with offices in Italy, US, and the Netherlands. |
| February-2022 | Dassault Systèmes announced strategic alliance for European digital sovereignty with Inria France’s National Institute for Research in Digital Science and Technology. The two entities have decided building a technological research roadmap confirming their joint ambition for creating a long-term disruptive technology in France and in Europe. |
